Navigation Links
Arpida Presents Data on Iclaprim at Scientific Congress in Germany
Date:11/2/2007

-drug resistant bacteria, including MRSA. We feel iclaprim could in the future play an important role in combating life-threatening infections caused by 'the superbug'."

The Phase I data presented in Kiel will be part of the NDA package that is expected to be submitted to the US Food and Drug Administration in the course of this year. Overall, the clinical programmes with iclaprim and the path towards the NDA filing for intravenous iclaprim in its first indication are on track. Patient enrolment into the Phase II studies with intravenous iclaprim in its second indication (HAP/VAP/HCAP) as well as into the Phase III trial with the TLT therapy in onychomycosis is expected to get underway shortly.

Arpida has a comfortable cash position, with cash and financial investments of CHF 95 million at the end of June 2007.

Arpida plans to give further updates on the progress of intravenous and oral iclaprim as well as TLT in the course of this year.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial close to NDA-filing and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent, pathogen-focused, late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007. An NDA filing is expected to take place in the second half of 2007.

In June 2007, Arpida announce
'/>"/>

SOURCE Arpida Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NimbleGen presents new tech for comparing microbe DNA
2. Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology
3. Thieme Presents Unique Technology Angle at Gov.s Conference
4. UW-Madisons Beebe wins scientific award
5. Researchers say scientific reporting needs more perspective, less hype
6. Wisconsin stands at the center of scientific efforts to avert flu epidemics
7. Growth prompts new location for scientific instrument manufacturer
8. UW stem cell guru outlines scientific and political future
9. Wisconsin biotech sector featured in scientific magazine
10. Scientific Protein Laboratories Acquired by New York firm
11. GenTel Appoints Burke to its Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- This report analyzes the worldwide markets for Bioinformatics in ... Biocontent. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
(Date:9/16/2014)... Mo. From cell phones to cars and ... life. Scientists and technology companies constantly are seeking ... for the first time using a water-based solution, ... a long-lasting and more efficient nuclear battery that ... a reliable energy source in automobiles and also ...
(Date:9/16/2014)... , Sept. 16, 2014  Donald Fresne, President and ... of Stephan Vagner , PhD to its Scientific Advisory ... of Toulouse, France , performed research at ... , and at Inserm, the French institute of health and ... works both at the Curie Institute, Orsay, France ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 ... initiatives to position themselves for their 89th ... labeling and encoding, Pharma Packaging Solutions is ... hardware and software and new procedures. Establishing ... Good Manufacturing Practices (cGMP), Pharma Packaging Solutions ...
Breaking Biology Technology:Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 2
... Q4 2007 sales increased 78.8% compared to Q4 2006 -- ... Estimated sales for FY ... increased 89.4% compared to FY 2006, NEW YORK, March ... a leading provider in the,nutraceutical industry engaged in the development, ...
... WELLESLEY HILLS, Mass., March 5 Joseph F. Finn, ... ActivBiotics, confirmed,today that the sale of ActivBiotics, proprietary assets ... PM on March 14, 2008. There has been,substantial interest ... 48 bid packages being reviewed by companies, in addition,to ...
... NEW YORK, March 5 Bristol-Myers Squibb,Company (NYSE: ... Board of Directors,has elected Jean-Marc Huet senior vice ... In this role, Mr. Huet will be,responsible for ... as the global financial operations of the organization ...
Cached Biology Technology:China Yingxia International Announces Q4 and FY 2007 Estimates 2China Yingxia International Announces Q4 and FY 2007 Estimates 3Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 2Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 3
(Date:9/16/2014)... . CRG researchers ... Journal of Cell Biology describes how Topo 2 ... , At this very moment thousands of our body,s cells ... the body repairs damaged tissues and regenerates others like skin ... "mitosis", during which the cell duplicates its genetic material and ...
(Date:9/16/2014)... Exxon Valdez spilled 11 million gallons of oil into ... another giant oil spill in the Gulf of Mexico ... Journal of Consumer Research , news coverage of ... of catalyzing changes in the way fossil fuels are ... coverage of these two events helped to resolve many ...
(Date:9/16/2014)... , Sept. 16, 2014  Valencell, Inc., a ... chosen as one of 18 "Showcase Companies" representing ... at the annual CED Tech Venture Conference on September ... Convention Center in Raleigh, North Carolina ... will lead a discussion during the "Digital Health Spotlight ...
Breaking Biology News(10 mins):Unraveling cell division 2Unraveling cell division 3Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2
... 1, 2011 Tiny marine organisms called zooplankton can use ... areas of the ocean where oxygen levels are so low ... trouble as these areas expand due to climate change. ... said University of Rhode Island doctoral student Leanne Elder. "But ...
... 2011 (Bronx, NY) A longstanding medical mystery ... other cognitive problems despite potent antiretroviral therapy may have ... of Yeshiva University. Their findings are published in the June ... Even though antiretroviral treatment suppresses HIV replication and slows ...
... study co-authored by University of Florida researchers provides details on ... concern as warm summer waters attract more people to the ... July print edition of Pacific Science warns that ... may be considered prey. The sharks feed near ...
Cached Biology News:Climate change could turn oxygen-free seas from blessing to curse for zooplankton 2New study documents first cookiecutter shark attack on a live human 2New study documents first cookiecutter shark attack on a live human 3
...
Human Aminopeptidase P1/XPNPEP1 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
streptavidin, Alexa Fluor® 750–allophycocyanin conjugate (Alexa Fluor® 750–allophycocyanin streptavidin) *1 mg/mL*...
AedestaTM Animal Organ/Tissue Perfusion Soln....
Biology Products: